Insmed Incorporated (INSM)
$16.75
Rating:
Recommendation:
Buy
| Symbol | INSM |
|---|---|
| Price | $16.75 |
| Beta | 1.567 |
| Volume Avg. | 1.32M |
| Market Cap | 2.285B |
| Shares () | - |
| 52 Week Range | 16.04-28.94 |
| 1y Target Est | - |
| DCF Unlevered | INSM DCF -> | |
|---|---|---|
| DCF Levered | INSM LDCF -> | |
| ROE | -867.19% | Strong Sell |
| ROA | -29.07% | Sell |
| Operating Margin | - | |
| Debt / Equity | 1783.36% | Strong Buy |
| P/E | -4.23 | Strong Sell |
| P/B | 23.43 | Strong Buy |
Latest INSM news
About
Download (Excel)Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.